ArticlePloS one2013
Evaluation of silk biomaterials in combination with extracellular matrix coatings for bladder tissue engineering with primary and pluripotent cells.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 52 citations in OpenAlex.
- The Future of Bladder Cancer Therapies: Integrating Hydrogel Scaffolds for Epigenetic Regulator Delivery.Cureus · 2025Review
- A Novel Hybrid Membrane for Urinary Conduit Substitutes Based on Small Intestinal Submucosa Coupled with Two Synthetic Polymers.Journal of functional biomaterials · 2022Article
- Development of a porcine acellular bladder matrix for tissue-engineered bladder reconstruction.Pediatric surgery international · 2022Article
- Silk films with nanotopography and extracellular proteins enhance corneal epithelial wound healing.Scientific reports · 2021Article
- Application of Adult and Pluripotent Stem Cells in Interstitial Cystitis/Bladder Pain Syndrome Therapy: Methods and Perspectives.Journal of clinical medicine · 2020Review
- A Review: Electrode and Packaging Materials for Neurophysiology Recording Implants.Frontiers in bioengineering and biotechnology · 2020Review
- Chondroinduction of Mesenchymal Stem Cells on Cellulose-Silk Composite Nanofibrous Substrates: The Role of Substrate Elasticity.Frontiers in bioengineering and biotechnology · 2020Article
- Tissue Engineering in Pediatric Bladder Reconstruction-The Road to Success.Frontiers in pediatrics · 2019Review
- Bioengineering Approaches for Bladder Regeneration.International journal of molecular sciences · 2018Review
- Stem Cells in Functional Bladder Engineering.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2016Review
- Silk Fibroin Scaffolds for Urologic Tissue Engineering.Current urology reports · 2016Review
- Differentiation of Human Induced-Pluripotent Stem Cells into Smooth-Muscle Cells: Two Novel Protocols.PloS one · 2016Article
- Dynamic reciprocity in cell-scaffold interactions.Advanced drug delivery reviews · 2015Review
- Production of urothelium from pluripotent stem cells for regenerative applications.Current urology reports · 2015Review
- In Vitro Evaluation of Spider Silk Meshes as a Potential Biomaterial for Bladder Reconstruction.PloS one · 2015Article
- Integration of proteomic and transcriptomic profiles identifies a novel PDGF-MYC network in human smooth muscle cells.Cell communication and signaling : CCS · 2014Article
- In vitro evaluation of bi-layer silk fibroin scaffolds for gastrointestinal tissue engineering.Journal of tissue engineering · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Silk-based biomaterials in combination with extracellular matrix (ECM) coatings were assessed as templates for cell-seeded bladder tissue engineering approaches. Two structurally diverse groups of silk scaffolds were produced by a gel spinning process and consisted of either smooth, compact multi-laminates (Group 1) or rough, porous lamellar-like sheets (Group 2). Scaffolds alone or coated with collagen types I or IV or fibronectin were assessed independently for their ability to support attachment, proliferation, and differentiation of primary cell lines including human bladder smooth muscle cells (SMC) and urothelial cells as well as pluripotent cell populations, such as murine embryonic stem cells (ESC) and induced pluripotent stem (iPS) cells. AlamarBlue evaluations revealed that fibronectin-coated Group 2 scaffolds promoted the highest degree of primary SMC and urothelial cell attachment in comparison to uncoated Group 2 controls and all Group 1 scaffold variants. Real time RT-PCR and immunohistochemical (IHC) analyses demonstrated that both fibronectin-coated silk groups were permissive for SMC contractile differentiation as determined by significant upregulation of α-actin and SM22α mRNA and protein expression levels following TGFβ1 stimulation. Prominent expression of epithelial differentiation markers, cytokeratins, was observed in urothelial cells cultured on both control and fibronectin-coated groups following IHC analysis. Evaluation of silk matrices for ESC and iPS cell attachment by alamarBlue showed that fibronectin-coated Group 2 scaffolds promoted the highest levels in comparison to all other scaffold formulations. In addition, real time RT-PCR and IHC analyses showed that fibronectin-coated Group 2 scaffolds facilitated ESC and iPS cell differentiation toward both urothelial and smooth muscle lineages in response to all trans retinoic acid as assessed by induction of uroplakin and contractile gene and protein expression. These results demonstrate that silk scaffolds support primary and pluripotent cell responses pertinent to bladder tissue engineering and that scaffold morphology and fibronectin coatings influence these processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.